Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-SARS-CoV-2 immunoglobulins (bovine colostrum)
- Development stage
- Phase 2
- Lead developer
- Razi Vaccine & Serum Research Institute
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral, Intravenous, Intranasal
01
Overview
**Anti-SARS-CoV-2 immunoglobulins (bovine colostrum)** are polyclonal antibodies specifically targeting SARS-CoV-2, derived from the colostrum of cows vaccinated with SARS-CoV-2 antigens[7][5][1]. These immunoglobulins act by binding to SARS-CoV-2 virions, blocking viral entry into host cells, and facilitating neutralization of the pathogen[7][5]. The colostrum of immunized cows is collected post-parturition and contains high concentrations of SARS-CoV-2-specific IgG (and other immunoglobulins), which can be administered orally, intranasally, or intravenously to confer passive immunity[7][5][4]. Mechanistically, these antibodies provide direct viral neutralization, potential prevention of infection, and immune modulation. This approach is under investigation as an adjunctive or prophylactic therapy for COVID-19, with demonstrated virus-neutralizing activity in vitro and initial human safety data (phase 1)[7][5][4].
- Brand names
- BioBlock
- Other names
- anti-COVID-19 hyperimmune immunoglobulins (bovine colostrum)hyperimmune bovine colostrum immunoglobulinsSARS-CoV-2-neutralizing antibodies (bovine colostrum)hyper-immune bovine colostrum
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on anti-SARS-CoV-2 immunoglobulins (bovine colostrum).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-SARS-CoV-2 immunoglobulins (bovine colostrum).